Wutah pendapatan taun lumaku: Kazia Therapeutics (KZIA)

Kazia Therapeutics focuses on the treatment of glioblastomas and rare oncological diseases, relying on payments from hospitals and insurance providers. The company enhances drug discovery efficiency through robotic genome analysis and automated cell imaging. Currently, Kazia Therapeutics is developing drugs designed to cross the blood-brain barrier. The TTM annual revenue change illustrates sales dynamics, where the 164.40 level reflects the current magnitude.
Kazia Therapeutics Limited - rincian analitis lan metrik utama (KZIA)

Year-over-year (TTM) sales growth measures revenue dynamics over the last twelve months relative to the same period last year, allowing investors to assess business scaling rates and the risk of capital stagnation. By analyzing TTM revenue volatility compared to the previous year, one can benchmark the financial results of Kazia Therapeutics (KZIA) against the operational efficiency of their oncology facilities and the modernization process of their sterile booths.